• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Vivesto

8.80 SEK+6.02 %16/7 17:29
Less than 1K followers

VIVE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+6.02 %
-3.30 %
+8.64 %
-15.71 %
-25.11 %
-56.33 %
-62.48 %
-96.61 %
-99.44 %

Vivesto is a pharmaceutical company focused on developing innovative treatments for serious oncology diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Vivesto was founded in 1988 and is headquartered in Uppsala, Sweden.

Read more
Market cap
97.43M SEK
Turnover
49.67K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13/8
2026

Interim report Q2'26

12/11
2026

Interim report Q3'26

11/2
2027

Annual report '26

Press release2026-07-01 10:04

DNB Carnegie Access: Vivesto: Cat study enrolment completed, results expected in Q4

Vivesto
Press release2026-07-01 08:00

Vivesto slutför rekryteringen i studie med Paccal Vet i katter och fastställer maximalt tolererbar dos

Vivesto
Press release2026-07-01 08:00

Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose

Vivesto

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-06-30 09:57

Finansinspektionen: Flaggningsmeddelande i Vivesto AB

Vivesto
Press release2026-06-26 13:59

DNB Carnegie Access: Vivesto: Paccal Vet top-line results expected in Q3

Vivesto
Press release2026-06-26 08:00

Vivesto slutför rekryteringen i pilotstudie med Paccal Vet i hundar – topline-resultat förväntas under tredje kvartalet 2026

Vivesto
Press release2026-06-26 08:00

Vivesto completes recruitment in Paccal Vet dog pilot study – topline results expected Q3 2026

Vivesto
Press release2026-06-26 08:00

Vivesto slutför rekryteringen i pilotstudie med Paccal Vet i hundar – topline-resultat förväntas under tredje kvartalet 2026

Vivesto
Press release2026-06-26 08:00

Vivesto completes recruitment in Paccal Vet dog pilot study – topline results expected Q3 2026

Vivesto
Regulatory press release2026-06-17 10:13

Finansinspektionen: Flaggningsmeddelande i Vivesto AB

Vivesto
Press release2026-06-16 10:30

DNB Carnegie Access: Vivesto: Positive data for Cantrixil

Vivesto
Press release2026-06-16 08:00

Vivesto rapporterar positiva resultat från PK/toxikologistudie med intravenöst Cantrixil

Vivesto
Press release2026-06-16 08:00

Vivesto reports positive results from i.v. Cantrixil PK/toxicology study

Vivesto
Regulatory press release2026-06-05 08:00

Vivesto utser Björn Svanström till CFO

Vivesto
Regulatory press release2026-06-05 08:00

Vivesto appoints Björn Svanström as CFO

Vivesto
Regulatory press release2026-06-02 11:06

Finansinspektionen: Flaggningsmeddelande i Vivesto AB

Vivesto
Regulatory press release2026-05-29 08:00

Nytt antal aktier och röster i Vivesto

Vivesto
Regulatory press release2026-05-29 08:00

New number of shares and votes in Vivesto

Vivesto
Press release2026-05-26 06:30

DNB Carnegie Access: Vivesto: Minor model adjustments

Vivesto
Regulatory press release2026-05-25 09:58

Finansinspektionen: Flaggningsmeddelande i Vivesto AB

Vivesto